bluebird bio to Resume Marketing of ZYNTEGLO in EU
At $2.8 Million, Beti-cel Is a Canary in the Drug Cost Coal Mine
ICER's Favorable Assessment Of Bluebird Bio's Gene Therapy Zynteglo May Have Important Pricing And Reimbursement Implications
bluebird claims first approval for gene therapy Zynteglo in EU -
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions - bluebird bio, Inc.
Somerville gene therapy firm bluebird bio nabs win with first FDA approval following split - Boston Business Journal
Bluebird puts €1.57m price on gene therapy Zynteglo - PMLiVE
Zynteglo: Gene Therapy for Beta-thalassemia • BioPharma Media
bluebird bio Inc., Undervalued Acquisition Candidate (NASDAQ:BLUE) | Seeking Alpha
SEC Filing - bluebird bio, Inc.
NEW | Bluebirdbio Releases Resources For Patients On Gene Therapy Zynteglo® – TIF
Potential blockbusters make a splash on market entry - Clarivate
bluebird bio gets CHMP nod for gene therapy Zynteglo | Pharmaphorum
SEC Filing - bluebird bio, Inc.
Bluebird wins U.S. approval for gene therapy for beta thalassemia - STAT
FDA Approves Bluebird's $2.8 Million Gene Therapy for Rare Blood Disease - WSJ
Bluebird Bio Withdraws Zynteglo From Germany Over Pricing :: Pink Sheet
blue-ex992_54.htm
FDA Approves bluebird bio's ZYNTEGLO®, the First Gene Therapy for People with Transfusion-Dependent Beta-Thalassemia - The Cooley's Anemia Foundation
Bluebird bio sets €1.6M price tag for rare blood disease gene therapy | S&P Global Market Intelligence
ZYNTEGLO® (betibeglogene autotemcel)
bluebird bio Launches Gene Therapy for Severe Blood Disorder in Germany | North Carolina Biotechnology Center
Patient group echoes bluebird bio stance over Zynteglo UK funding snub
NICE turns down bluebird bio's gene therapy Zynteglo - PMLiVE
Bluebird Bio To Resume Zynteglo Gene Therapy Marketing In Europe After Positive Recommendation From PRAC
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
FDA Approves $2.8 million Gene Tx - Zynteglo - Anton Health
Bluebird bio's gene therapy Zynteglo could have high price tag defense in beta thalassemia - Pharmaceutical Technology
Bluebird Bio Resumes Marketing Of Gene Therapy Zynteglo For β-Thalassaemia In Europe – TIF
